X

Trial Profile

Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trial

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Malignant thymoma
Focus Therapeutic Use
Acronyms PRIMER

Most Recent Events

13 Apr 2019 As the early termination criterion (less than one responder) was fulfilled during the first stage, the study was deemed futile and was terminated as per results published in the European Journal of Cancer
13 Apr 2019 Results published in the European Journal of Cancer
03 Oct 2017 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com